NTLA-2001
ATTR Amyloidosis (Cardiomyopathy/Polyneuropathy)
Phase 3Active (Study Completed)
Key Facts
Indication
ATTR Amyloidosis (Cardiomyopathy/Polyneuropathy)
Phase
Phase 3
Status
Active (Study Completed)
Company
About Intellia Therapeutics
Intellia Therapeutics is a leader in translating Nobel Prize-winning CRISPR/Cas9 technology into transformative genomic medicines. The company's strategy leverages a dual-platform approach—in vivo and ex vivo editing—to advance a pipeline targeting rare genetic diseases like hereditary angioedema (HAE) and ATTR amyloidosis, with key programs in late-stage development. Backed by a strong intellectual property foundation and a strategic partnership with Regeneron, Intellia is building toward becoming a fully integrated, commercial-stage biopharmaceutical company.
View full company profile